GPR21 and metabolic syndrome: To this purpose, a recent paper by Romero-Nava et al. showed a change in the genetic expression of GPR21 in different in vivo experimental models of metabolic syndrome, thus suggesting its involvement in the pathogenesis of this condition and the hypothesis of a role for this receptor as a new therapeutic target [50].